首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1532509

心臟衰竭POC 和LOC 設備市場- 按測試類型（蛋白質體學、代謝組學、基因組學）、技術（微流體、基於陣列的系統）、最終用途（醫院、專科診所、輔助生活和家庭護理環境） - 全球預測（2024 年 -第2032章

Heart Failure POC and LOC Devices Market - By Test Type (Proteomic, Metabolomic, Genomic), Technology (Microfluidics, Array-based Systems), End-use (Hospitals, Specialty Clinics, Assisted Living & Homecare Settings) - Global Forecast (2024 - 2032)

出版日期: 2024年05月21日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在醫療基礎設施改善的推動下，2024 年至 2032 年全球心臟衰竭 POC 和 LOC 設備市場複合年成長率將超過 16.4%。根據世界衛生組織的數據，2022 年全球醫療保健支出達到 8.3 兆美元，反映出對先進醫療技術的投資不斷成長。

隨著醫療保健系統的現代化，人們更加重視將先進的診斷技術融入日常實踐中。這項發展提高了檢測和管理心臟衰竭的可及性和效率。在已開發國家和新興國家，對醫療保健設施的投資和技術的採用促進了心臟衰竭照護端 POC 和晶片實驗室 LOC 設備的更廣泛可用性，從而實現更快、更準確的診斷。這些進步滿足了對創新診斷解決方案日益成長的需求，並改善了患者的治療效果，有利於市場前景。

心臟衰竭 POC 和 LOC 設備產業根據技術、測試類型、最終用途和地區進行分類。

基於陣列的系統部分在預測期內將經歷顯著的複合年成長率，因為它們能夠在單次測試中提供高通量分析。基於陣列的系統提供了一種多重方法，能夠同時測量與心臟衰竭相關的多個生物標記。此功能提高了診斷準確性和效率，有助於更早檢測和更有效地管理病情。隨著醫療保健提供者尋求透過更詳細和快速的診斷來最佳化患者的治療結果，基於陣列的系統在用於心臟衰竭的 POC 和 LOC 設備中的採用預計會增加。

由於對個人化醫療的需求不斷成長，到 2032 年，代謝組學檢測領域將佔據顯著的市場佔有率。該測試提供了對代謝特徵的詳細了解，從而提高了心臟衰竭診斷和管理的準確性。隨著醫療保健日益轉向個人化方法，在照護端或透過晶片實驗室技術進行快速、詳細分析的能力支持更客製化的治療計劃。這種向精準醫學的轉變推動了對先進診斷設備的需求，這些設備可以快速提供全面的代謝資料，改善患者的治療結果。

由於對創新醫療解決方案和高醫療支出的關注，北美心臟衰竭 POC 和 LOC 設備產業將在 2024 年至 2032 年間實現可觀的複合年成長率。北部擁有完善的醫療基礎設施，人們對心臟病的認知不斷提高，並強調透過早期準確的診斷來改善患者的治療結果。對精準醫療的日益重視，加上強力的醫療保健政策和資金，增加了對先進心臟衰竭監測和診斷設備的需求，推動了區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 心臟衰竭和心血管疾病的盛行率不斷增加
  - 診斷技術的進步
  - 政府措施和醫療保健政策
- 產業陷阱與挑戰
  - 嚴格的監管環境
  - 與這些設備相關的高成本
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

主要趨勢
蛋白質體測試
代謝組學測試
基因組檢測

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

主要趨勢
微流控
基於陣列的系統
其他技術

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
專科診所
輔助生活醫療設施
家庭護理設置
其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abaxis, Inc.
Abbott Laboratories
Becton, Dickinson and Company
bioMerieux S.A.
BioTelemetry, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Instrumentation Laboratory
Jant Pharmacal Corporation
Masimo Corporation
Novartis AG
Quidel Corporation
Siemens Healthineers AG
Stryker Corporation
Trinity Biotech

簡介目錄

Product Code: 9564

Global Heart Failure POC and LOC Devices Market will showcase over 16.4% CAGR from 2024 to 2032, driven by improved healthcare infrastructure. According to the World Health Organization, global healthcare spending reached USD 8.3 trillion in 2022, reflecting a growing investment in advanced medical technologies.

As healthcare systems modernize, there is a greater emphasis on integrating advanced diagnostic technologies into routine practice. This development enhances accessibility and efficiency in detecting and managing heart failure. In both developed and emerging nations, investments in healthcare facilities and technology adoption facilitate broader availability of heart failure Point-of-Care POC and Laboratory-on-a-Chip LOC devices, enabling quicker and more accurate diagnoses. Such advancements improve patient outcomes by meeting the increasing demand for innovative diagnostic solutions, favoring the market outlook.

The heart failure POC and LOC devices industry is categorized based on technology, test type, end-use, and region.

The array-based systems segment will experience a significant CAGR during the forecast period, owing to their ability to provide high-throughput analysis in a single test. Array-based systems offer a multiplexed approach, enabling simultaneous measurement of multiple biomarkers associated with heart failure. This capability enhances diagnostic accuracy and efficiency, facilitating earlier detection and more effective management of the condition. As healthcare providers seek to optimize patient outcomes through more detailed and rapid diagnostics, the adoption of array-based systems in POC and LOC devices for heart failure is expected to increase.

The metabolomic testing segment will hold a noteworthy market share by 2032, because of the growing need for personalized medicine. This test provides detailed insights into metabolic profiles, which improve the precision of heart failure diagnosis and management. As healthcare increasingly shifts toward personalized approaches, the ability to perform rapid, detailed analyses at the point of care or through laboratory-on-a-chip technologies supports more tailored treatment plans. This shift towards precision medicine thrusts the demand for advanced diagnostic devices that quickly deliver comprehensive metabolic data, improving patient outcomes.

North America heart failure POC and LOC devices industry will witness a promising CAGR between 2024 and 2032, due to the focus on innovative healthcare solutions and high medical spending. North With a well-established healthcare infrastructure, there is a heightened awareness of heart disease and an emphasis on improving patient outcomes through early and accurate diagnosis. This growing emphasis on precision medicine, coupled with robust healthcare policies and funding, elevates the demand for advanced heart failure monitoring and diagnostic devices, fueling the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of heart failure and cardiovascular diseases
  - 3.2.1.2 Advancements in diagnostic technologies
  - 3.2.1.3 Government initiatives and healthcare policies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory landscape
  - 3.2.2.2 High cost associated with these devices
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Proteomic testing
5.3 Metabolomic testing
5.4 Genomic testing

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Microfluidics
6.3 Array-based systems
6.4 Other technologies

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Assisted living healthcare facilities
7.5 Homecare settings
7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa